Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease

Golabi, Pegah; Gerber, Lynn H.; Paik, James; Deshpande, Rati; Avila, Leyla de; Younossi, Zobair M.

doi:10.1016/j.jhepr.2020.100171

Cited by 74 publications

(69 citation statements)

References 41 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,33 A recent study analysing the NHANES 1999-2004 dataset reported a close association between sarcopenia-related NAFLD defined using noninvasive panels and mortality consistent with our study. 34 The third NHANES (1988)(1989)(1990)(1991)(1992)(1993)(1994)) is a unique database as it included details of hepatic ultrasonography. Therefore, we utilized this database to add uniform objectivity and improve the accuracy of the definition of NAFLD.…”

Section: Discussionmentioning

confidence: 99%

“…The strengths of our study included a longer follow-up period (median follow-up 23.2 vs 13.5 years), larger sample size (11 065 vs 4611), and a significantly higher number of outcomes (3342 vs 587 deaths). 34 Although there was substantial follow-up mortality data up to 13.5 years, we hypothesized that a longer follow-up period spanning over 25 years may allow us to establish an independent association of ultrasonographically-defined NAFLD with all-cause and cause-specific mortality based on the natural history of NAFLD characterized by its slow progression. In addition, our study showed that individuals with NAFLD and coexisting sarcopenia were noted to have an increased risk of diabetes-related mortality.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States

Kim

Wijarnpreecha

Sandhu

et al. 2021

Liver International

View full text Add to dashboard Cite

Background & Aims: Nonalcoholic fatty liver disease (NAFLD) has been associated with sarcopenia. However, mortality in the setting of NAFLD-related sarcopenia remains undefined. We aim to determine the all-cause and cause-specific mortality from sarcopenia among adults with NAFLD in the USA. Methods: 11 065 individuals in the Third National Health and Nutrition Examination Survey were studied and linked mortality through 2015 was analysed. NAFLD was diagnosed based on presence of ultrasonographic hepatic steatosis without other known liver diseases. Sarcopenia was defined as skeletal muscle index determined by bioelectrical impedance analysis. The Cox proportional hazard model was used to assess all-cause mortality and cause-specific mortality, and hazard ratio (HR) adjusted for known risk factors.Results: During a median follow-up of 23 years or more, sarcopenia was associated with increased all-cause mortality (HR 1.27, 95% confidence interval [CI] 1.11-1.44). Only in individuals with NAFLD, sarcopenia was associated with a higher risk for all-cause mortality, while this association was absent in those without NAFLD. Individuals with both sarcopenia and NAFLD had a higher risk for all-cause mortality (HR 1.28 95% CI 1.06-1.55) compared with those without sarcopenia and NAFLD. Furthermore, sarcopenia was associated with a higher risk for cancer-and diabetesrelated mortality among those with NAFLD. This association was not noted in those without NAFLD. Conclusion:In this nationally representative sample of US adults, sarcopenia was associated with a higher risk for all-cause, cancer-and diabetes-related mortality in individuals with NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States

Kim

Wijarnpreecha

Sandhu

et al. 2021

Liver International

View full text Add to dashboard Cite

show abstract

“…This means that those subjects with high BMI are less likely to be classified as having sarcopenia. Therefore, weight-adjusted or BMI-adjusted sarcopenia indices are more appropriate in patients with nonalcoholic fatty liver disease (NAFLD), which is associated with obesity [18,70,71]. The FNIH definition proposed sex-specific cutoff values of the sarcopenia index, in which the ASM is divided by BMI (men < 0.789 and women < 0.521) [25].…”

Section: Dual Energy X-ray Absorptiometry (Dxa)mentioning

confidence: 99%

“…The FNIH definition proposed sex-specific cutoff values of the sarcopenia index, in which the ASM is divided by BMI (men < 0.789 and women < 0.521) [25]. This cutoff value has mainly been used in research on NAFLD [18,71]. In addition, some researchers defined the lowest quintile of the ASM_BMI as sarcopenia [19], or defined sarcopenia using upper limb muscle mass [68,72].…”

Section: Dual Energy X-ray Absorptiometry (Dxa)mentioning

confidence: 99%

Definition of Sarcopenia in Chronic Liver Disease

Son

Song

Chang

et al. 2021

Life

View full text Add to dashboard Cite

Sarcopenia, which is characterized by decline in muscle mass, muscle strength, and physical performance, is common in patients with chronic liver disease (CLD) and is associated with poor clinical outcomes. Several consensus definitions for community-dwelling elderly people have been proposed, and these recommend the use of various tools and tests to assess muscle properties and performance. These measurement tools have also been applied in patients with CLD and have been useful for predicting prognosis. However, sarcopenia and its diagnostic criteria specific to patients with CLD have not yet been clearly defined. In addition, fluid retention and body composition should be considered when sarcopenia is assessed in patients with CLD. This review aims to introduce definitions of sarcopenia and diagnostic tools used in patients with CLD.

show abstract

“…Owing to the rapid decline in physical activity of the general population resulting from the global scale lockdown due to the COVID-19 pandemic and prolonged restriction of movement with the resultant increase in telecommuting, there are concerns regarding various components of metabolic syndrome, muscle weakness, and other health problems [5]. Moreover, people who previously engaged in physical activity, including commuting to work, may rapidly develop inactivity-induced fatty liver [6]. However, this cannot be assessed over a short time without continuous measurements.…”

Section: Discussionmentioning

confidence: 99%

Rapid Onset of Weight Gain and Liver Dysfunction Successfully Treated With Nutrition and Exercise

Kamimura¹,

Sano²,

Tsujimura³

et al. 2021

Cureus

View full text Add to dashboard Cite

Physical inactivity is one of the causes of most metabolic syndromes. The incidence of metabolic syndrome is expected to increase in the near future because of the reduced opportunities for exercise caused by COVID-19. Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease. Changes in diet and lifestyle have led to a dramatic increase in the prevalence of NAFLD in the world. NAFLD is characterized by excessive triglyceride (TG) accumulation in the hepatocytes due to both increased inflow of free fatty acids and de novo hepatic lipogenesis. Thus far, no study quantitatively assessed the liver fat deposition after a rapid decline in physical activity. Herein, we describe a case of a 17year-old Japanese boy with severe fat infiltration of the liver, due to a rapid decline in physical activity, treated at our facility. Our rehabilitation and nutritional support teams administered appropriate exercise and nutrition support to reduce weight and improve liver dysfunction. Our findings support dietary changes and exercise therapy to manage such cases.

show abstract

Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease

Cited by 74 publications

References 41 publications

Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States

Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States

Definition of Sarcopenia in Chronic Liver Disease

Rapid Onset of Weight Gain and Liver Dysfunction Successfully Treated With Nutrition and Exercise

Contact Info

Product

Resources

About